A 74-year-old man presents to the clinic for a routine check-up for management of chronic stable angina and is found to have a total protein level of 8.4 g/dL (Normal: 6.0–8.0). He feels well and denies bone pain, fatigue, or weight loss. Vital signs are within normal limits. Physical examination is unremarkable, with no lymphadenopathy or organomegaly.
Laboratory studies show the following:
Hemoglobin: 14.1 g/dL
Calcium: 9.4 mg/dL
Creatinine: 0.9 mg/dL
Serum protein electrophoresis (SPEP): M-spike of 1.8 g/dL (IgG type)
Bone marrow biopsy: 6% clonal plasma cells
Skeletal survey: No lytic lesions or fractures
Which of the following is the most appropriate next step in management?
The correct answer is:
A) Clinical observation and repeat labs in 6 months
This patient has monoclonal gammopathy of undetermined significance (MGUS). MGUS is a common, asymptomatic plasma cell dyscrasia found in roughly 3% of the population over age 50 years. It is considered a precursor to multiple myeloma (MM), but most patients with MGUS will never progress to overt malignancy. The diagnostic criteria for MGUS are:
Serum M-protein < 3.0 g/dL
Bone marrow clonal plasma cells < 10%
Absence of CRAB symptoms (No Hypercalcemia, Renal insufficiency, Anemia, or Bone lesions) attributable to the plasma cell proliferative disorder.
Because MGUS is a premalignant condition without end-organ damage, the standard of care is observation. Treatment (chemotherapy or transplant) is reserved for patients who progress to multiple myeloma or smoldering myeloma with high-risk features.
Answer choice B: Initiate therapy with bortezomib and lenalidomide, is incorrect. Bortezomib (a proteasome inhibitor) and lenalidomide (an immunomodulatory drug) are treatments for multiple myeloma. Since this patient is asymptomatic and does not meet the criteria for MM, these aggressive interventions are not indicated and would cause unnecessary toxicity.
Answer choice C: Perform an autologous stem cell transplant, is incorrect. Autologous stem cell transplant is a treatment for multiple myeloma. Since this patient is asymptomatic and does not meet the criteria for MM, this intervention is not indicated.
Answer choice D: Schedule a radical nephrectomy, is incorrect. Radical nephrectomy is a treatment for renal cell carcinoma. While multiple myeloma can cause renal failure (myeloma kidney), it does not cause solid renal masses. MGUS does not affect renal function.
Answer choice E: Start high-dose intravenous dexamethasone, is incorrect. High-dose steroids are used in the induction phase of multiple myeloma or to treat acute complications like hypercalcemia or cord compression. They have no role in the management of asymptomatic MGUS.
Key Learning Point
MGUS is defined by an M-spike < 3.0 g/dL, < 10% plasma cells in the marrow, and the absence of CRAB symptoms. The risk of progression to multiple myeloma is approximately 1% per year. Patients should be monitored regularly with SPEP and CBC, but they do not require active treatment.
Feature | MGUS | Smoldering Myeloma | Multiple Myeloma |
M-protein | < 3.0 g/dL | ≥ 3.0 g/dL | ≥ 3.0 g/dL |
B.M. Plasma Cells | < 10% | 10–60% | > 10% |
CRAB Symptoms | None | None | Present |
